Get the Stockscreener App
60.35
1.00%
0.60
Disc Medicine Inc stock is traded at $60.35, with a volume of 349.10K.
It is up +1.00% in the last 24 hours and down -0.64% over the past month.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
See More
Previous Close:
$59.75
Open:
$60.01
24h Volume:
349.10K
Relative Volume:
0.96
Market Cap:
$2.10B
Revenue:
-
Net Income/Loss:
$-91.00M
P/E Ratio:
-16.44
EPS:
-3.67
Net Cash Flow:
$-74.38M
1W Performance:
+0.82%
1M Performance:
-0.64%
6M Performance:
+10.67%
1Y Performance:
+23.79%
1-Day Range:
$59.75
$61.05
1-Week Range:
$57.54
$64.83
52-Week Range:
$30.82
$68.73
Disc Medicine Inc Stock (IRON) Company Profile
Name
Disc Medicine Inc
Sector
Industry
Phone
(617) 674-9274
Address
321 ARSENAL STREET, SUITE 101, WATERTOWN
Compare IRON with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRON
Disc Medicine Inc
|
60.35 | 2.05B | 0 | -91.00M | -74.38M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jun-11-25 | Resumed | Raymond James | Strong Buy |
| Feb-27-25 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-04-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-23-24 | Initiated | Jefferies | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-22-24 | Initiated | Wells Fargo | Overweight |
| Apr-01-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-19-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-09-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jun-07-23 | Initiated | H.C. Wainwright | Buy |
| May-17-23 | Initiated | Raymond James | Outperform |
| Apr-28-23 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-21-23 | Initiated | Stifel | Buy |
| Apr-20-23 | Initiated | Morgan Stanley | Overweight |
| Mar-23-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Disc Medicine Inc Stock (IRON) Latest News
Morgan Stanley Assumes Coverage of Disc Medicine (IRON) With $85 PT - MSN
Can Disc Medicine Inc. Bounce Back From Weekly LowWeekly Volume Report & Technical Pattern Alert System - classian.co.kr
Is Disc Medicine Inc. in a long term uptrendJuly 2025 Rallies & Real-Time Chart Pattern Alerts - newsyoung.net
Bitterman Kevin, director at Disc Medicine, sells $1.96m in iron stock - Investing.com Canada
Disc Medicine’s (IRON) Rising Net Losses Could Be a Game Changer for Its Financial Strategy - simplywall.st
Disc Medicine Inc. Stocks Attracting Dip BuyersEarnings Recap Report & Target Return Focused Stock Picks - beatles.ru
Disc Medicine,Inc. shares rise 2.40% intraday after BioRestorative Therapies reported Q2 2025 financial results and clinical program milestones. - AInvest
Disc Medicine Reports Q2 2025 Financial Results and Clinical Progress - TipRanks
Disc Medicine (IRON) Q2 Loss Widens 109% - AOL.com
Disc Medicine Director Bitterman Kevin Sells 395 Shares at $60.95/Share on 08/05/2025. - AInvest
Disc Medicine: Strong Financial Position and Promising Drug Pipeline Justify Buy Rating - TipRanks
Disc Medicine Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Disc Medicine Misses On Losses But Keeps Wall Street Optimistic - Finimize
Disc Medicine Stumbles On Earnings But Analysts Stay Bullish - Finimize
Disc Medicine (IRON) Q2 Loss Widens 109% - The Motley Fool
Disc Medicine Shares Fall After Wider-Than-Expected Q2 Loss - MarketScreener
Disc Medicine reports Q2 EPS ($1.58), consensus ($1.14) - TipRanks
Disc Medicine Reports Second Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Disc Medicine, Inc. SEC 10-Q Report - TradingView
Disc Medicine Q2 loss bigger than expected as costs increase - TradingView
Disc Medicine Earnings: FDA Filing Timeline Set for EPP Drug as Cash Reserves Hit $650M Milestone - Stock Titan
How strong is Disc Medicine Inc. company’s balance sheetInvest confidently with real-time market updates - Jammu Links News
Is Disc Medicine Inc. a good long term investmentDiscover dynamic stocks ready to soar - Jammu Links News
Is it the right time to buy Disc Medicine Inc. stockMarket-leading growth rates - Jammu Links News
What catalysts could drive Disc Medicine Inc. stock higher in 2025Achieve consistent double-digit growth - Jammu Links News
What analysts say about Disc Medicine Inc. stockMaximize portfolio growth with professional advice - Jammu Links News
Is Disc Medicine Inc. a growth stock or a value stockMarket-beating performance - Jammu Links News
Published on: 2025-08-03 11:24:58 - Jammu Links News
What are analysts’ price targets for Disc Medicine Inc. in the next 12 monthsBuild a winning investment strategy today - Jammu Links News
How many analysts rate Disc Medicine Inc. as a “Buy”Realize exceptional returns through smart trading - Jammu Links News
How does Disc Medicine Inc. generate profit in a changing economyHigh-octane investment opportunities await - Jammu Links News
Insider Selling at Disc Medicine Inc.: A Signal or a Symptom? - AInvest
Is Disc Medicine Inc. stock overvalued or undervaluedLow Risk Report For Consistent Profits - Jammu Links News
Institutional Investors in Disc Medicine, Inc. (NASDAQ:IRON) See US$140m Decrease in Market Cap Last Week, Although Long-term Gains Have Benefitted Them. - 富途牛牛
Why Disc Medicine Inc. stock attracts strong analyst attentionNews Based Entry Opportunity Alerts Detected - metal.it
How does Disc Medicine Inc. compare to its industry peersExpert Picks Watchlist For 2025 - Jammu Links News
Disc Medicine's NDA Submission for Bitopertin in EPP: A High-Probability Catalyst for Value Creation - AInvest
Disc Medicine, Inc. (IRON) Set to Submit NDA for Bitopertin in October 2025 - Insider Monkey
What is the dividend policy of Disc Medicine Inc. stockMaximize gains with strategic stock entries - Jammu Links News
Are Investors Undervaluing Disc Medicine, Inc. (NASDAQ:IRON) By 49%? - Yahoo Finance
How volatile is Disc Medicine Inc. stock compared to the marketBreakneck growth rates - jammulinksnews.com
Disc Medicine Inc Stock (IRON) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):